➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Colorcon
Merck
Boehringer Ingelheim
Mallinckrodt

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Gliolan

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Gliolan?

Gliolan is an investigational drug.

There have been 15 clinical trials for Gliolan. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.

The most common disease conditions in clinical trials are Glioblastoma, Glioma, and Brain Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), University Hospital, Lille, and Institut National de la Santé Et de la Recherche Médicale, France.

There are one hundred and eight US patents protecting this investigational drug and seven hundred and sixty-one international patents.

Recent Clinical Trials for Gliolan
TitleSponsorPhase
Dose Finding for Intraoperative Photodynamic Therapy of GlioblastomaInstitut National de la Santé Et de la Recherche Médicale, FrancePhase 2
Dose Finding for Intraoperative Photodynamic Therapy of GlioblastomaUniversity Hospital, LillePhase 2
Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent GlioblastomaDeutsche Krebshilfe e.V., Bonn (Germany)Phase 2

See all Gliolan clinical trials

Clinical Trial Summary for Gliolan

Top disease conditions for Gliolan
Top clinical trial sponsors for Gliolan

See all Gliolan clinical trials

US Patents for Gliolan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gliolan   Start Trial Method for the treatment of acne DUSA PHARMACEUTICALS, INC. (Wilmington, MA)   Start Trial
Gliolan   Start Trial Multispectral wide-field endoscopic imaging of fluorescence University of Washington (Seattle, WA)   Start Trial
Gliolan   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
Gliolan   Start Trial Theranostics platform and methods of use Sanford Burnham Prebys Medical Discovery (La Jolla, CA)   Start Trial
Gliolan   Start Trial Genetically modified microorganism for producing medium-chain lauric acid and/or dodecanedioic acid and method of using thereof INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (Hsinchu, TW)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gliolan

Drugname Country Document Number Estimated Expiration Related US Patent
Gliolan Australia 2013299487 2032-08-10   Start Trial
Gliolan Canada 2881439 2032-08-10   Start Trial
Gliolan European Patent Office 2882432 2032-08-10   Start Trial
Gliolan World Intellectual Property Organization (WIPO) 2014026077 2032-08-10   Start Trial
Gliolan Australia 2017261372 2036-05-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Colorcon
Merck
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.